RG9MTD2 Inhibitors
RG9MTD2 inhibitors encompasses a range of compounds that are designed to interact specifically with the enzyme RG9MTD2, which is a member of the methyltransferase family. Methyltransferases are enzymes that catalyze the transfer of methyl groups from donor molecules such as S-adenosylmethionine (SAM) to acceptor substrates, which can be nucleic acids, proteins, or other molecules. The specificity of RG9MTD2 inhibitors lies in their ability to bind to the active site or regulatory regions of the RG9MTD2 enzyme, thereby modulating its function. The precise action of these inhibitors depends on the structure of the molecules involved in the inhibition process, which can vary widely among different inhibitors within this class.
The development of RG9MTD2 inhibitors involves extensive research into the structure and function of the RG9MTD2 enzyme, including understanding the three-dimensional conformation of the enzyme and the mechanisms by which it interacts with its substrates. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are often employed to elucidate these details. Once the interaction sites and mechanisms are understood, chemists can design inhibitors that are complementary in shape and charge to the active or allosteric sites of RG9MTD2. The chemical structures of these inhibitors might include a variety of functional groups that enable them to form non-covalent interactions, such as hydrogen bonds, ionic bonds, and hydrophobic interactions, with the enzyme, thereby affecting its function. The fine-tuning of these molecular interactions is crucial for the development of specific inhibitors that exhibit high selectivity for RG9MTD2 over other methyltransferases or biological macromolecules.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 is a potent inhibitor of the bromodomain and extra-terminal (BET) family of proteins, which can indirectly suppress the expression of certain downstream genes that may be critical for the activity of RG9MTD2. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that promotes hyperacetylation of histones, leading to alterations in chromatin structure that could affect gene expression profiles, including genes that might impact the function of RG9MTD2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which blocks the MAPK/ERK pathway. By inhibiting this pathway, protein phosphorylation and activity regulated by this pathway could be disrupted, potentially affecting proteins involved in the same cellular processes as RG9MTD2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which blocks the PI3K/AKT signaling pathway. This can lead to inhibitory effects on downstream processes that may indirectly impact the functional activity of RG9MTD2 by affecting its associated signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which can affect protein synthesis and cellular proliferation. Since RG9MTD2 may be involved in these cellular processes, its activity could be indirectly inhibited by disturbances in mTOR signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor which can inhibit multiple protein kinases, potentially affecting the phosphorylation status of proteins that play a role in the same pathways or processes that involve RG9MTD2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which could indirectly impede the function of RG9MTD2 by interfering with the MAPK/ERK pathway, a pathway that may be essential for the processes in which RG9MTD2 is involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, altering the JNK signaling pathway, which could modify the activity of transcription factors and other proteins that are involved in the same biological processes as RG9MTD2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which can change the phosphorylation state of proteins involved in the p38 MAPK pathway. This alteration may indirectly affect RG9MTD2 if it is associated with this pathway. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is a neutral sphingomyelinase inhibitor, which could influence sphingolipid signaling pathways. Disruption of these pathways may impact the function of RG9MTD2 if it is associated with lipid signaling or metabolism. | ||||||